This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahaffey, K. W. Articles by Becker, R. C. Search for Related Content PubMed PubMed Citation Articles by Mahaffey, K. W. Articles by Becker, R. C. Related Collections Deep vein thrombosis Other anticoagulants Coagulation and fibronolysis Related Article

(Circulation. 2006;114:2313-2316.)
© 2006 American Heart Association, Inc.

Editorial

The Scientific Community’s Quest to Identify Optimal Targets for Anticoagulant Pharmacotherapy

Kenneth W. Mahaffey, MD; Richard C. Becker, MD

From the Duke Clinical Research Institute (K.W.M., R.C.B.) and Cardiovascular Thrombosis Center (R.C.B.), Duke University School of Medicine, Durham, NC.

Correspondence to R.C. Becker, MD, Professor of Medicine, Cardiology and Hematology, Duke University School of Medicine, Durham, NC 27705. E-mail becke021@mc.duke.edu

Key Words: Editorials • anticoagulants • pharmacology • thrombosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The scientific community’s quest to identify optimal targets for anticoagulant pharmacotherapy must be soundly based on fundamental constructs of vascular biology and coagulation. Although this tenet, which has served as a platform for drug development during the past 50 years, is incontrovertible, one should also ask, "What experimental model of coagulation is most applicable and directly translatable to mammalian coagulation in general and to human thrombotic disorders in particular?" Is it the "waterfall-cascade" or "autoprothrombin model" of blood coagulation first described by Macfarlane¹ and Davie and Ratnoff² that so elegantly described inactive precursors being converted to active proteases in a sequential series of bioamplification steps? Or is it a cell-based model of coagulation^3,4 that portrays an integrated and functional representation of complex biochemical events occurring on cellular surfaces in lieu of functionally independent cascades that principally reflect clot formation in static fluid systems rather than the dynamic interplay of tissue factor (TF)-bearing cells, platelets, and their respective protein intermediaries? Or is it a cumulative 4-component model based on numerical approximations of TF-mediated thrombin generation, TF activation of the blood coagulation proteome, TF-activated and contact pathway–inhibited whole blood in vitro, and blood shed from standardized microvascular wounds in vivo as an interactive paradigm of real-time events?⁵ Clearly, each model honestly represents, with increasing biochemical rigor, authenticity, and translatable convergence, blood coagulation under normal and pathological conditions. The remaining step, which provides a personalized stamp toward translating experimental models to human biology with concerted effort and safe, effective, and patient- and disease-specific . . . [Full Text of this Article]

Related Article:

Issue Highlights
Circulation 2006 114: 2305. [Extract] [Full Text]

This article has been cited by other articles:

				M. Y. Chan, M. G. Cohen, C. K. Dyke, S. K. Myles, L. G. Aberle, M. Lin, J. Walder, S. R. Steinhubl, I. C. Gilchrist, N. S. Kleiman, et al. Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease Circulation, June 3, 2008; 117(22): 2865 - 2874. [Abstract] [Full Text] [PDF]